Rare condition

Unclassified myelodysplastic syndrome

0

studies recruiting now

as of 7 Sept 2026

1

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

1 study is registered for Unclassified myelodysplastic syndrome, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Keep watching

Get an email when a new Unclassified myelodysplastic syndrome study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Unclassified myelodysplastic syndrome

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Treatments being studied

17 approved treatments and 119 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Doxecitine (Doxecitine component of mt-1621 2'-deoxycytidine)Approved: Thioguanine (Lanvis)Approved: AclarubicinApproved: IdarubicinApproved: Daunorubicin (Daunorubicin component of vyxeos)Approved: UbenimexApproved: Gemtuzumab Ozogamicin (Mylotarg)Approved: Enasidenib Mesylate (Idhifa)Approved: Olutasidenib (Rezlidhia)Approved: GilteritinibApproved: Midostaurin (Rydapt)Approved: Tagraxofusp (Elzonris)Approved: Ivosidenib (Tibsovo)Approved: LestaurtinibApproved: Uracil Mustard (Uracil mustard)Approved: QuizartinibApproved: Apalutamide (Erleada)
Phase 3Guadecitabine
Phase 3Elacridar
Phase 3Peginterferon Lambda-1a
Phase 3Sapacitabine
Phase 3Tipifarnib
Phase 3Valspodar (Amdray)
Phase 3Cpi 613
Phase 3Tasisulam

+ 111 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).